LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

Search

Fate Therapeutics Inc

Gesloten

SectorGezondheidszorg

1.14 2.7

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.09

Max

1.16

Belangrijke statistieken

By Trading Economics

Inkomsten

3.6M

-34M

Verkoop

278K

1.9M

Winstmarge

-1,786.576

Werknemers

181

EBITDA

979K

-37M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+215.32% upside

Dividenden

By Dow Jones

Volgende Winsten

10 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

31M

138M

Vorige openingsprijs

-1.56

Vorige sluitingsprijs

1.14

Nieuwssentiment

By Acuity

50%

50%

169 / 372 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Fate Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 aug 2025, 23:09 UTC

Acquisities, Fusies, Overnames

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 4th Update

22 aug 2025, 22:02 UTC

Acquisities, Fusies, Overnames

Agreement Could Also Lead to Deeper Collaboration Between CSX, BNSF

22 aug 2025, 22:02 UTC

Acquisities, Fusies, Overnames

Some Analysts Say Agreement Suggests Lack of Confidence in Merger

22 aug 2025, 22:02 UTC

Acquisities, Fusies, Overnames

CSX, BNSF Intermodal Pact Draws Competing Views on Merger Possibility

22 aug 2025, 22:02 UTC

Acquisities, Fusies, Overnames

CSX, BNSF Pact Sparks Debate on Whether Another Rail Merger Is Approaching -- Analysis

22 aug 2025, 22:02 UTC

Acquisities, Fusies, Overnames

Pact Could Show Regulators That Transcontinental Service Can Come Without Merger

22 aug 2025, 21:23 UTC

Marktinformatie

Moody's Lowers Outlook on Austria to Negative From Stable -- Market Talk

22 aug 2025, 21:18 UTC

Marktinformatie

US Economic Growth Seen Slowing This Year -- Market Talk

22 aug 2025, 21:18 UTC

Acquisities, Fusies, Overnames

U.S. Takes 10% Stake in Intel -- Barrons.com

22 aug 2025, 21:03 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 aug 2025, 21:03 UTC

Marktinformatie

Mexican Stocks Close At Record High -- Market Talk

22 aug 2025, 20:58 UTC

Marktinformatie

US General Government Deficit Expected to Rise in 2026, 2027 -- Market Talk

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: Government's Investment in Intel Will Be a Passive Ownership, With No Bd Representation or Other Governance or Info Rights >INTC

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: Government Also Agrees to Vote With the Company's Bd of Directors on Matters Requiring Shareholder Approval, With Limited Exceptions >INTC

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: Government Equity Stake Will Be Funded by Remaining $5.7B in Grants Previously Awarded, But Not Yet Paid, Under U.S. CHIPS and Science Act and $3.2B Awarded as Part of Secure Enclave Program >INTC

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: Government Agrees to Purchase 433.3M Primary Shrs of Intel Common Stk at a Price of $20.47 per Shr, Equivalent to a 9.9% Stake in Co >INTC

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: U.S. Government to Make $8.9B Investment in Intel Common Stk as Co Builds Upon Its More Than $100B Expansion of Resilient Semiconductor Supply Chain >INTC

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: Intel and Trump Admin Reach Historic Agreement to Accelerate Amer Technology and Manufacturing Leadership

22 aug 2025, 20:56 UTC

Winsten

These Stocks Moved the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 aug 2025, 20:55 UTC

Winsten

These Stocks Are Moving the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 aug 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

22 aug 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

22 aug 2025, 20:41 UTC

Acquisities, Fusies, Overnames

U.S. Has 10% Stake in Intel, Lutnick Says -- Barrons.com

22 aug 2025, 20:24 UTC

Acquisities, Fusies, Overnames

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 3rd Update

22 aug 2025, 20:16 UTC

Acquisities, Fusies, Overnames

CSX and Warren Buffett's BNSF Made News. Why Investors Are Disappointed. -- Barrons.com

22 aug 2025, 19:19 UTC

Marktinformatie

Boeing to Restart Talks With Defense Workers' Union Monday -- Market Talk

22 aug 2025, 19:10 UTC

Marktinformatie

Oil Futures Gain as Russia-Ukraine Peace Seems Distant -- Market Talk

22 aug 2025, 19:06 UTC

Marktinformatie

U.S. Natural Gas Extends Losses as Summer Nears an End -- Market Talk

22 aug 2025, 19:03 UTC

Marktinformatie

Lower Borrowing Rates Elusive Even if Fed Cuts -- Market Talk

22 aug 2025, 18:52 UTC

Acquisities, Fusies, Overnames

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 2nd Update

Peer Vergelijking

Prijswijziging

Fate Therapeutics Inc Prognose

Koersdoel

By TipRanks

215.32% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.5 USD  215.32%

Hoogste 6 USD

Laagste 2 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fate Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

2

Buy

5

Hold

0

Sell

Technische score

By Trading Central

0.9101 / 1.14Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

169 / 372 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.